A novel approach using a zwitterionic sulfobetaine-based surfactant for the synthesis of spherical copper oxide nanoparticles (Cu 2 O NPs) has been applied. For the first time, N-hexadecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate has been used as stabilizer to control the size and morphology of Cu 2 O NPs. Several techniques, such as transmission electron microscopy (TEM), X-ray diffraction (XRD), and fluorescence spectroscopy, are used to investigate the size, structure, and optical properties of synthesized Cu 2 O nanocrystals. The results indicate that copper(I) oxide nanoparticles with size in the range of 2 to 45 nm and crystalline structure, exhibit intense yellow fluorescence (λ em = 575 nm). Furthermore, the cytotoxicity studies show that sulfobetaine-stabilized copper oxide nanoparticles prompt inhibition of cancer cell proliferation in a concentration-dependent manner, however, the adverse effect on the normal cells has also been observed. The results indicate that the sulfobetaine-stabilized Cu 2 O, because of their unique properties, have a potential to be applied in medical fields, such as cancer therapy and bioimaging.
No takes yet. Share an insight, caveat, or question.
Woźniak-Budych et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: